Published in

Wiley, Alimentary Pharmacology and Therapeutics, 10(33), p. 1162-1172, 2011

DOI: 10.1111/j.1365-2036.2011.04635.x

Links

Tools

Export citation

Search in Google Scholar

IL28B polymorphisms, IP‐10 and viral load predict virological response to therapy in chronic hepatitis C

Journal article published in 2011 by Giovanna Fattovich, Loredana Covolo, Stéphanie Bibert, Galia Askarieh, Martin Lagging, Sophie Clément, Giovanni Malerba, Michela Pasino, Maria Guido, Massimo Puoti, Giovanni B. Gaeta, Gaeta Gb, Teresa Santantonio, Giovanni Raimondo, Raffaele Bruno ORCID and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract BACKGROUND: Hepatitis C virus (HCV) is a major cause of chronic liver disease, cirrhosis and hepatocellular carcinoma and the identification of the predictors of response to antiviral therapy is an important clinical issue. AIM: To determine the independent contribution of factors including IL28B polymorphisms, IFN-gamma inducible protein-10 (IP-10) levels and the homeostasis model assessment of insulin resistance (HOMA-IR) score in predicting response to therapy in chronic hepatitis C (CHC). METHODS: Multivariate analysis of factors predicting rapid (RVR) and sustained (SVR) virological response in 280 consecutive, treatment-naive CHC patients treated with peginterferon alpha and ribavirin in a prospective multicentre study. RESULTS: Independent predictors of RVR were HCV RNA